These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30190975)

  • 1. Predicting recurrence following radiofrequency percutaneous ablation for hepatocellular carcinoma.
    Ganne-Carrié N; Nault JC; Ziol M; N'Kontchou G; Nahon P; Grando V; Bourcier V; Barge S; Beaugrand M; Trinchet JC; Seror O
    Hepat Oncol; 2014 Oct; 1(4):395-408. PubMed ID: 30190975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of radiofrequency ablation as first-line therapy for hepatocellular carcinoma less than 3 cm in potentially transplantable patients.
    Doyle A; Gorgen A; Muaddi H; Aravinthan AD; Issachar A; Mironov O; Zhang W; Kachura J; Beecroft R; Cleary SP; Ghanekar A; Greig PD; McGilvray ID; Selzner M; Cattral MS; Grant DR; Lilly LB; Selzner N; Renner EL; Sherman M; Sapisochin G
    J Hepatol; 2019 May; 70(5):866-873. PubMed ID: 30615906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors.
    Kim YS; Rhim H; Cho OK; Koh BH; Kim Y
    Eur J Radiol; 2006 Sep; 59(3):432-41. PubMed ID: 16690240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence-free survival after radiofrequency ablation of hepatocellular carcinoma. A registry report of the impact of risk factors on outcome.
    Zytoon AA; Ishii H; Murakami K; El-Kholy MR; Furuse J; El-Dorry A; El-Malah A
    Jpn J Clin Oncol; 2007 Sep; 37(9):658-72. PubMed ID: 17766723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm.
    Mohkam K; Dumont PN; Manichon AF; Jouvet JC; Boussel L; Merle P; Ducerf C; Lesurtel M; Rode A; Mabrut JY
    J Hepatol; 2018 Jun; 68(6):1172-1180. PubMed ID: 29410287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive factors of survival and intrahepatic recurrence of hepatocellular carcinoma in cirrhosis after percutaneous ethanol injection: analysis of 71 patients.
    Castellano L; Calandra M; Del Vecchio Blanco C; de Sio I
    J Hepatol; 1997 Nov; 27(5):862-70. PubMed ID: 9382974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Factors after Percutaneous Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma. Impact of Incomplete Ablation on Recurrence and Overall Survival Rates.
    Sparchez Z; Mocan T; Radu P; Mocan LP; Sparchez M; Leucuta DC; Al Hajjar N
    J Gastrointestin Liver Dis; 2018 Dec; 27(4):399-407. PubMed ID: 30574622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.
    Yang PC; Ho CM; Hu RH; Ho MC; Wu YM; Lee PH
    World J Hepatol; 2016 Nov; 8(31):1309-1317. PubMed ID: 27872682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for hepatocellular carcinoma.
    Jeon HJ; Eun HS; Kwon IS; Lee BS; Lee ES; Rou WS; Sung JK; Moon HS; Kang SH; Lee HS; Kim SH; Chun K; Kim SH
    Surg Endosc; 2023 Jul; 37(7):5176-5189. PubMed ID: 36947227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of laparoscopic liver resection versus radiofrequency ablation in patients with early and small hepatocellular carcinoma: an updated meta-analysis and meta-regression of observational studies.
    Shaaban Abdelgalil M; Amer BE; Yasen N; El-Samahy M; Awad AK; Elfakharany B; Saeed O; Abd-ElGawad M
    World J Surg Oncol; 2024 Feb; 22(1):47. PubMed ID: 38326841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for the recurrence of early hepatocellular carcinoma treated by percutaneous radiofrequency ablation with a multiple-electrode switching system: a multicenter prospective study.
    Tan Y; Wang X; Ma K; Zhang L; Li J; Chen P; Zhang B
    Int J Hyperthermia; 2022; 39(1):190-199. PubMed ID: 35042449
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation.
    Nicolini D; Svegliati-Baroni G; Candelari R; Mincarelli C; Mandolesi A; Bearzi I; Mocchegiani F; Vecchi A; Montalti R; Benedetti A; Risaliti A; Vivarelli M
    World J Gastroenterol; 2013 Sep; 19(34):5622-32. PubMed ID: 24039354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Younger hepatocellular carcinoma patients have better prognosis after percutaneous radiofrequency ablation therapy.
    Kao WY; Chiou YY; Hung HH; Su CW; Chou YH; Huo TI; Huang YH; Wu WC; Lin HC; Lee SD; Wu JC
    J Clin Gastroenterol; 2012 Jan; 46(1):62-70. PubMed ID: 21934530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laparoscopic ablation therapies or hepatic resection in cirrhotic patients with small hepatocellular carcinoma.
    Santambrogio R; Bruno S; Kluger MD; Costa M; Salceda J; Belli A; Laurent A; Barabino M; Opocher E; Azoulay D; Cherqui D
    Dig Liver Dis; 2016 Feb; 48(2):189-96. PubMed ID: 26675381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting long-term outcomes of early-stage hepatocellular carcinoma after primary curative treatment: the role of surgical or nonsurgical methods.
    Kuo MJ; Mo LR; Chen CL
    BMC Cancer; 2021 Mar; 21(1):250. PubMed ID: 33685409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance and predictive factors of early massive recurrence after radiofrequency ablation in patients with a single small hepatocellular carcinoma.
    Cho JY; Choi MS; Lee GS; Sohn W; Ahn J; Sinn DH; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW
    Clin Mol Hepatol; 2016 Dec; 22(4):477-486. PubMed ID: 28081587
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Japanese experience in ablation therapies for hepatocellular carcinoma.
    Shiina S
    Hepatol Res; 2007 Sep; 37 Suppl 2():S223-9. PubMed ID: 17877487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and circulating biomarkers of survival and recurrence after radiofrequency ablation in patients with hepatocellular carcinoma.
    Canale M; Ulivi P; Foschi FG; Scarpi E; De Matteis S; Donati G; Ercolani G; Scartozzi M; Faloppi L; Passardi A; Tamburini E; Valgiusti M; Marisi G; Frassineti GL; Casadei Gardini A
    Crit Rev Oncol Hematol; 2018 Sep; 129():44-53. PubMed ID: 30097237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SQSTM1 Expression in Hepatocellular Carcinoma and Relation to Tumor Recurrence After Radiofrequency Ablation.
    Abdel-Moety A; Baddour N; Salem P; El-Tobgy H; El-Shendidi A
    J Clin Exp Hepatol; 2022; 12(3):774-784. PubMed ID: 35677515
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.